BI appoints new CMO

Dr Thor Voigt is retiring from Boehringer Ingelheim after a 27 year tenure. Dr Mehdi Shahidi, present Oncology Global Head at BI has been appointed to replace him to become the new Corporate Senior Vice President Medicine and Chief Medical Officer.

Allan Hillgrove, Corporate Board Division Human Pharma, said: “In the pharmaceutical industry, the medical function is at the core of our success, which is based on the improvement we can provide to the health of patients.  We are fortunate to have many strong leaders in this area, and thank Dr Voigt for his excellent contributions. He will have a great successor in Dr Shahidi who takes over this important role as Chief Medical Officer with a well-deserved, excellent reputation inside and outside our company.”